drugset / Trial / NCT03832179

Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification

NCT03832179

Phase 4 Completed 16 enrolled Bay Area Retina Associates Allergan · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to compare the efficacy of antecedent intravitreal anti-vascular endothelial growth factor therapy vs. Ozurdex in reducing post-cataract surgery related macular edema in patients with pre-existing diabetic macular edema.

Timeline

Start
2018-11-15
Primary completion
2023-09-01
Completion
2024-03-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aflibercept Protein / enzyme biologic Intravitreal
Comparator Bevacizumab Monoclonal antibody Intravitreal
Subject Dexamethasone Small molecule Intravitreal
Comparator Ranibizumab Monoclonal antibody Intravitreal